Profile data is unavailable for this security.
About the company
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).
- Revenue in USD (TTM)57.31m
- Net income in USD-8.12m
- Incorporated2001
- Employees62.00
- LocationMolecular Templates Inc9301 Amberglen Blvd Ste 100AUSTIN 78729-1153United StatesUSA
- Phone+1 (512) 896-1555
- Fax+1 (302) 655-5049
- Websitehttps://mtem.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galera Therapeutics Inc | 0.00 | -59.08m | 9.94m | 7.00 | -- | -- | -- | -- | -1.42 | -1.42 | 0.00 | -2.41 | 0.00 | -- | -- | 0.00 | -168.38 | -83.69 | -227.94 | -97.54 | -- | -- | -- | -- | -- | -4.78 | 7.60 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
| Medical Marijuana Inc | -100.00bn | -100.00bn | 10.02m | -- | -- | 0.1078 | -- | -- | -- | -- | -- | 0.019 | -- | -- | -- | -- | -- | -22.66 | -- | -23.11 | -- | 70.58 | -- | -145.52 | 1.79 | -- | 0.0479 | -- | 26.30 | 39.07 | 141.59 | -- | -0.016 | -- |
| Organovo Holdings Inc | 242.00k | -19.09m | 10.04m | 15.00 | -- | 1.59 | -- | 41.49 | -2.17 | -2.17 | 0.0275 | 0.6283 | 0.0143 | -- | 4.44 | 12,100.00 | -112.40 | -51.24 | -123.59 | -54.90 | -- | -- | -7,886.36 | -1,269.78 | -- | -- | 0.00 | -- | -75.33 | -39.60 | -50.76 | -- | 5.99 | -- |
| BioCardia Inc | 477.00k | -11.57m | 10.20m | 16.00 | -- | -- | -- | 21.38 | -0.5525 | -0.5525 | 0.0225 | -0.0677 | 0.0747 | -- | 3.61 | 29,812.50 | -181.08 | -107.34 | -414.21 | -154.17 | -- | -- | -2,425.79 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
| Guardion Health Sciences Inc | 12.25m | 158.03k | 10.25m | 9.00 | 64.22 | 1.25 | 57.75 | 0.8366 | 0.1243 | 0.1243 | 9.66 | 6.39 | 0.729 | 2.36 | 5.83 | 1,360,951.00 | 0.9405 | -77.90 | 1.12 | -86.55 | 44.04 | 42.45 | 1.29 | -176.93 | 6.98 | -- | 0.00 | -- | 10.85 | 67.03 | 101.00 | -- | -58.56 | -- |
| Kazia Therapeutics Ltd (ADR) | 14.66k | -13.30m | 10.25m | 12.00 | -- | 1.13 | -- | 699.63 | -0.8065 | -0.8065 | 0.0008 | 0.3433 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| 22nd Century Group Inc | 32.20m | -64.68m | 10.31m | 64.00 | -- | -- | -- | 0.3202 | -49.97 | -116.47 | 29.49 | -3.09 | 0.4531 | 5.70 | 8.81 | 503,187.50 | -76.94 | -46.78 | -105.06 | -54.18 | -27.00 | -2.11 | -169.81 | -107.95 | 0.4766 | -4.62 | 2.39 | -- | -20.49 | 4.03 | -76.94 | -- | 53.60 | -- |
| ELEVAI Labs Inc | 1.71m | -4.30m | 10.47m | 18.00 | -- | 2.74 | -- | 6.11 | -0.2482 | -0.2482 | 0.0988 | 0.2208 | -- | -- | -- | 95,143.89 | -- | -- | -- | -- | 66.25 | -- | -251.17 | -- | 3.41 | -41.16 | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 10.49m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| BioNexus Gene Lab Corp | 9.77m | -2.63m | 10.51m | 30.00 | -- | 1.09 | -- | 1.08 | -0.1389 | -0.1389 | 0.6873 | 0.5466 | 0.9703 | 7.98 | 5.33 | -- | -26.11 | -3.83 | -31.86 | -5.02 | 13.61 | 14.55 | -26.91 | -3.04 | 4.24 | -186.19 | 0.00 | -- | -10.60 | 115.07 | -638.56 | -- | 30.40 | -- |
| Psyence Biomedical Ltd | 0.00 | 1.52m | 10.69m | -- | -- | -- | 7.05 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
| Molecular Templates Inc | 57.31m | -8.12m | 10.80m | 62.00 | -- | 2.09 | -- | 0.1884 | -1.55 | -1.55 | 12.74 | 0.7837 | 0.8622 | -- | -- | 924,290.30 | -12.22 | -51.78 | -27.76 | -73.14 | -- | -- | -14.18 | -228.33 | -- | -7.24 | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
| Monopar Therapeutics Inc | 0.00 | -8.40m | 11.47m | 10.00 | -- | 1.75 | -- | -- | -0.612 | -0.612 | 0.00 | 0.3749 | 0.00 | -- | -- | 0.00 | -81.69 | -54.07 | -107.13 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| Viaderma Inc | 17.80m | 2.31m | 11.55m | 75.00 | 0.0006 | 0.00004 | 2.13 | 0.6489 | 16.84 | 16.84 | 129.62 | 255.59 | 0.4126 | 24.69 | 1.21 | 237,331.30 | 5.36 | -- | 6.53 | -- | 28.90 | -- | 12.99 | -- | 2.07 | 5.66 | 0.1718 | -- | -29.15 | -- | -40.70 | -- | -- | -- |
Data as of Apr 24 2024. Currency figures normalised to Molecular Templates Inc's reporting currency: US Dollar USD
50.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bellevue Asset Management AGas of 31 Dec 2023 | 1.03m | 19.16% |
| BVF Partners LPas of 31 Dec 2023 | 532.04k | 9.90% |
| SilverArc Capital Management LLCas of 31 Dec 2023 | 354.61k | 6.60% |
| Adage Capital Management LPas of 31 Dec 2023 | 292.76k | 5.45% |
| Caxton Corp.as of 31 Dec 2023 | 136.87k | 2.55% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 124.61k | 2.32% |
| Monashee Investment Management LLCas of 31 Dec 2023 | 121.84k | 2.27% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 39.65k | 0.74% |
| Geode Capital Management LLCas of 31 Dec 2023 | 36.71k | 0.68% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 23.65k | 0.44% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
